Jones Financial Companies’s KalVista Pharmaceuticals KALV Stock Holding History

Jones Financial Companies’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.22K	Buy	+63	New	+$1.01K	﹤0.01%	4300

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jones Financial Companies's KALV Position: Q1 2026 in Review

Jones Financial Companies opened a new position in KalVista Pharmaceuticals (KALV) in Q1 2026: 63 shares worth $1.22K. The stake represents ﹤0.01% of the portfolio and ranks #4300 among its holdings.

184 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Jones Financial Companies held 63 shares of KalVista Pharmaceuticals worth $1.22K as of Q1 2026.
KalVista Pharmaceuticals was a new Jones Financial Companies position in Q1 2026.
KalVista Pharmaceuticals made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #4300 holding.
184 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.